Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds

Funded Grants

Back to results

Novel blood and neuroimaging markers of Alzheimer’s disease and cerebral amyloid angiopathy

Project Overview

As our brains age, they become vulnerable to diseases such as Alzheimer’s disease which can cause dementia. Dementia is defined as cognitive (i.e., thinking) problems that interfere with usual daily activities. In the milder stages of dementia, this includes difficulty with shopping, finances, and cooking. As dementia progresses, difficulties with basic activities arise–such as bathing and dressing–typically leading to a need for placement in an assisted living facility and, ultimately, causing death. Because of the aging of our population, dementia is becoming more common. Within 25 years it is expected that more than one million Canadians will have dementia.Although doctors can recognize the symptoms of full blown dementia, it is much harder to diagnose the brain diseases that cause it. As a result, there is a need for better diagnostic tests for the diseases that cause dementia. The most common cause of dementia is Alzheimer’s disease, caused by the build-up of two abnormally folded proteins in the brain, called beta-amyloid and tau. The beta-amyloid affects the blood vessels too, causing a sister condition called cerebral amyloid angiopathy. Our objective is to develop and validate diagnostic tests for Alzheimer’s disease and cerebral amyloid angiopathy, based on a blood sample and MRI scan. We have strong preliminary (i.e., early) data that we can detect misfolded proteins and other markers in the blood of patients with Alzheimer’s disease or mild cognitive impairment, and that we can use brain MRI scans to measure the early effects on brain connections and blood vessels. We are now asking for funding to thoroughly test these markers. If our ideas are correct, then we will have developed the world’s first accurate blood tests for Alzheimer’s disease and cerebral amyloid angiopathy, as well as brain MRI scan techniques that allow doctors to determine the prognosis.

Principal Investigator

Eric Smith , University of Calgary

Team Members

Nils Daniel Forkert, University of Calgary

Christian Beaulieu, University of Alberta

David Hogan, University of Calgary

Bruce Pike, Montreal Neurological Hospital and Institute

Richard Frayne, University of Calgary

Nikolai Malykhin, University of Alberta

Liang Li, University of Alberta

Roger Dixon, University of Alberta

Peter Stys, University of Calgary

Partners and Donors

Alberta Innovates Health Solutions

Alzheimer Society of Alberta & Northwest Territories

Campus Alberta Neuroscience

Project Complete

Novel blood and neuroimaging markers of Alzheimer’s disease and cerebral amyloid angiopathy

  • Grant Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    2015 MIRI Team Grants

  • Province

    Alberta

  • Start Date

    2016

  • Total Grant Amount

    $1,387,500

  • Health Canada Contribution

    $693,750

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

+1 (514) 989-2989 info@braincanada.ca

Please note all online donations will receive an electronic tax receipt, issued by Brain Canada Foundation.

Our Donors

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign Up

Territorial acknowledgement

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations. We honour and pay respect to elders past, present and emerging, and dedicate ourselves to moving forward in the spirit of partnership, collaboration, and reconciliation. In our work, we focus our efforts on the Truth and Reconciliation Commission’s Calls to Action, particularly those that pertain to improving health for Indigenous Peoples and that focus on advancing our own learning on Indigenous issues.

© 2025 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co

  • About
    • What We Do
    • EDI Action Plan
    • Leadership
    • Team
    • Annual Report
    • Publications
    • Careers
  • Brain Conditions
    • One Brain
    • ALS
    • Autism (ASD)
    • Brain Cancer
    • Brain Injury
    • Dementia
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • More
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
    • Research Impact Stories
    • Equity, Diversity and Inclusion
    • Brain Health in Indigenous Communities
    • Women’s Brain Health
    • Mind Over Matter
  • How You Can Help
    • Ways to Give
    • Start a Fundraiser
    • Workplace Giving
    • The Great Minds
Project Directory
Donate Now